Veru reaches agreement with fda on new phase 3 clinical trial for sabizabulin for broader indication: hospitalized adult patients with any type of viral acute respiratory distress syndrome (ards)

--reached agreement with fda on single phase 3 clinical trial design to expand treatment population to include all hospitalized adult patients with any type of virus induced ards including the “tripledemic viruses”: influenza, rsv, and sars-cov-2-- -- based on high mortality rate for viral ards, expected sabizabulin phase 3 study size is 408 patients with all-cause mortality at day 60 as the primary endpoint--
VERU Ratings Summary
VERU Quant Ranking